17 completed, 2 terminated, 1 unknown. 10 Phase 2, 9 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 9, Unknown 1 |
| Phase 1 | 9 | Completed 7, Terminated 2 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow PF-00299804: new trials by email Literature Review of PF-00299804 trials Research Report on PF-00299804
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer Dacomitinib - Skin Squamous Cell Cancer | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 43 | 2014-11-01 | 2016-07-04 |
| Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Dacomitinib - Penile Neoplasms, Carcinoma, Squamous Cell | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 32 | 2013-06-15 | 2021-05-14 |
| Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck dacomitinib, Radiotherapy, Cisplatin - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | University Health Network, Toronto | 12 | 2013-01-01 | 2016-06-13 |
| A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma PF-00299804 - Head and Neck Squamous Cell Carcinoma | Not applicable | Completed | University Health Network, Toronto | 6 | 2011-12-01 | 2015-07-10 |
| PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma PF-00299804 - Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent | Phase 2 | Completed | Yonsei University | 49 | 2011-10-01 | 2014-09-30 |
| A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer PF-02341066, PF-00299804 - Non Small Cell Lung Cancer | Phase 1 | Completed | Pfizer | 70 | 2010-08-01 | 2015-10-28 |
| PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer PF00299804 - Advanced Gastric Cancer, HER2 | Phase 2 | Completed | Seoul National University Hospital | 28 | 2010-07-01 | 2015-11-20 |
| Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment PF-00299804 - Oral Cavity Cancer | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 13 | 2010-05-01 | 2015-07-10 |
| PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma PF-00299804 - Glioblastoma, GBM | Phase 2 | Completed | Massachusetts General Hospital | 58 | 2010-04-01 | 2018-08-16 |
| A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804 PF-00299804 - Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Terminated | Pfizer | 22 | 2010-02-01 | 2012-06-22 |
| PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer PF-00299804, Placebo - Lung Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 720 | 2009-12-23 | 2023-08-22 |
| A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks PF-00299804 - Carcinoma, Non-Small Cell, Neoplasm Metastasis | Phase 1 | Completed | Pfizer | 74 | 2008-12-15 | 2024-04-22 |
| Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer PF-00299804 - Head and Neck Neoplasms | Phase 2 | Completed | Pfizer | 69 | 2008-11-04 | 2021-02-09 |
| A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen Erlotinib, PF-00299804 - Non-small Cell Lung Cancer | Phase 2 | Completed | Pfizer | 188 | 2008-11-01 | 2015-10-07 |
| A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors PF-00299804 - Neoplasms | Phase 1 | Completed | Pfizer | 13 | 2008-11-01 | 2011-06-27 |
| A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients PF-00299804 - Advanced Malignant Solid Tumors | Phase 1 | Completed | Pfizer | 16 | 2008-09-01 | 2017-08-02 |
| PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib PF-00299804 - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Pfizer | 66 | 2008-04-29 | 2019-05-21 |
| Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer PF-00299804 - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Pfizer | 55 | 2008-02-05 | 2020-10-19 |
| Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors PF-00299804 - Neoplasms | Phase 1 | Completed | Pfizer | 121 | 2005-10-11 | 2018-12-21 |
Carcinoma, Non-Small-Cell Lung (6) · Carcinoma, Squamous Cell (4) · Neoplasm Metastasis (3) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Carcinoma (1) · Glioblastoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Pfizer (10) · University Health Network, Toronto (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Massachusetts General Hospital (1) · NCIC Clinical Trials Group (1) · OHSU Knight Cancer Institute (1) · Seoul National University Hospital (1) · Yonsei University (1)
United States (10) · Canada (6) · South Korea (5) · Australia (3) · Italy (3) · Brazil (2) · Spain (2) · Taiwan (2) · Argentina (1) · France (1) · Hong Kong (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Peru (1)
Andrea Necchi, MD (1) · Byoung Chul Cho, M.D.,Ph.D. (1) · Lara Davis, MD (1) · Lillian Siu, M.D. (1) · Lillian Siu, MD (1) · Lillian Siu, MD, FRCPC (1) · Michael Millward, MD (1) · Paolo Bossi, MD (1) · Penny Bradbury, MD (1) · Peter Ellis, MD (1) · Roberto Salvioni, MD (1) · Tracy T. Batchelor, MD (1) · Yung-Jue Bang, MD, PhD (1)
PMID 21220471, PMID 22249430, PMID 24501009, PMID 25057165, PMID 25439692, PMID 25521398, PMID 25937431, PMID 26581547, PMID 26768165, PMID 26889973, PMID 39863139
2005 (1), 2008 (1)